Should You Buy Zoetis Stock At This Price?
Zoetis (ZTS) stock trades at a discount, with a P/E of 13.5x vs. 22.3x for the median S&P 500 company. It has lost 29.6% over the past year. Zoetis maintains high operating margins (37.7%) but faces slowing revenue growth (0.9% YoY) and declining dermatology sales. The company is introducing new pet medicine versions and offering discounts to combat market share loss.
How this was made
The 30-second read
Why it matters
The narrowed guidance signals a shift from prior growth expectations, likely prompting a short‑term price decline.
Market read
Guidance cut is the primary catalyst for ZTS price movement; peers may be affected.
What to watch
Potential upside from upcoming Cytopoint approval and discount strategies could mitigate revenue decline.
Background
Zoetis is a leading animal health company whose stock has fallen 30% YTD amid slowing pet‑care sales.
Ticker impact
Zoetis narrowed FY2026 revenue guidance to $9.22‑$9.32 B, down 1‑2% YoY, and warned of flat 2027 sales.
likely pressure as investors price in slower growth and lower margins
Guidance is a primary disclosure that directly reduces expectations for revenue and earnings, prompting a sell‑side reaction.
Market effects
Pet health sector may see broader valuation pressure as growth slows.
U.S. animal health stocks could face modest downside.
Limited; impact confined to Zoetis and peers.
Counterpoint
If new product launches succeed, the guidance cut may be overly cautious, offering a buying opportunity.
Key entities
- CompanyZoetis Inc.
Animal health products maker.
